We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Avidity Biosciences Inc | NASDAQ:RNA | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 1.92 | 7.96% | 26.05 | 25.40 | 26.05 | 26.97 | 23.9215 | 24.15 | 1,167,144 | 23:36:29 |
From May 2021 to May 2024
By Colin Kellaher
Avidity Biosciences Inc. on Monday said the U.S. Food and Drug Administration granted fast-track designation to AOC 1001, its lead program, for the genetic multisystem disorder myotonic dystrophy type 1.
The biopharmaceutical company said there are currently no approved treatments for the progressive and often fatal disease, which primarily affects skeletal and cardiac muscle.
The FDA's fast-track program is designed to facilitate the development and expedite the review of treatments for serious or potentially life-threatening illnesses with high unmet medical needs.
The FDA previously cleared Avidity to proceed with a Phase 1/2 study of AOC 1001 in adults with myotonic dystrophy type 1.
Shares of Avidity, which closed Friday at $21.52, rose 4.6% in premarket trading Monday.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
October 18, 2021 09:39 ET (13:39 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
1 Year Avidity Biosciences Chart |
1 Month Avidity Biosciences Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
